Australia has rolled out a first-of-its-kind respiratory syncytial virus (RSV) protection program that targets the most vulnerable populations: pregnant women and infants under 6 months old. The National RSV Mother and Infant Protection Program, which began on February 3, 2025, provides free access to RSV vaccines and monoclonal antibodies through the National Immunisation Program (NIP). This marks a significant shift in how public health systems approach a virus that hospitalizes thousands of Australian children every year.

Why Is RSV Such a Serious Threat to Infants?

RSV is a common respiratory virus that most children encounter before age two. While it often causes mild cold-like symptoms in healthy adults, it can trigger severe lower respiratory infections in vulnerable groups. In infants, RSV can lead to bronchiolitis, a serious inflammation of the small airways in the lungs that sometimes requires hospitalization.

The numbers tell a sobering story. Between 2016 and 2019, Australia recorded more than 115,000 hospitalizations with an RSV diagnosis, with approximately 75% involving children under 5 years old. For the tiniest patients, infants under 6 months, the annual hospitalization rate reached approximately 3,100 per 100,000 population. The rate climbed even higher for newborns aged 0 to 2 months, hitting approximately 4,000 per 100,000 population.

RSV spreads through respiratory droplets from coughs and sneezes. These droplets can be inhaled directly or land on surfaces where the virus survives for several hours, making it highly contagious in households and childcare settings.

How Does Australia's New Protection Strategy Work?

The new program uses two complementary approaches to shield infants from severe RSV disease. The strategy recognizes that infants cannot be vaccinated directly in their first months of life, so protection comes through two pathways: maternal vaccination and direct infant protection.

• Maternal Vaccination: Pregnant women receive a single dose of the Abrysvo vaccine between 28 weeks gestation and delivery. The vaccine triggers the mother's immune system to produce antibodies that pass to the developing baby, providing passive immunity from birth.
• Infant Monoclonal Antibodies: Eligible infants receive Beyfortus (nirsevimab), a long-acting monoclonal antibody administered as an injection. This provides direct protection during the infant's first RSV season, typically autumn and winter months.
• Older Monoclonal Antibody Option: Synagis (palivizumab), available in Australia for many years, remains approved for infants and young children at high risk of severe RSV disease, though it requires multiple doses.

The timing of RSV season varies by region. In most temperate areas of Australia, seasonal outbreaks occur during autumn and winter, typically between April and September, with peaks in June and July. In tropical regions, the pattern is less pronounced and may align with rainy seasons.

Who Is Eligible for Free RSV Protection?

The program prioritizes the highest-risk populations. Pregnant women of all ages are eligible for free Abrysvo vaccination for each pregnancy starting at 28 weeks gestation. Infants are eligible for free Beyfortus during their first RSV season, though specific eligibility criteria apply based on risk factors.

The program also extends to older adults. Beginning May 15, 2026, the RSV vaccine Arexvy will be funded under the NIP for all adults aged 75 years and over, as well as Aboriginal and Torres Strait Islander adults aged 60 years and over. Adults aged 60 and older with underlying medical conditions that increase their risk of severe RSV disease are also eligible.

RSV hospitalization rates increase again in late adulthood, making older adults another critical population for protection. The virus can cause pneumonia and exacerbate existing lung conditions like asthma in this age group.

Steps to Ensure Your Family Gets RSV Protection

• If You're Pregnant: Discuss RSV vaccination with your healthcare provider at your 28-week prenatal visit. The Abrysvo vaccine is available free under the NIP and can be administered at any point from 28 weeks gestation through delivery.
• If You Have a Newborn: Ask your pediatrician or maternal and child health nurse about Beyfortus eligibility for your infant. The monoclonal antibody is most effective when given early in the RSV season.
• If You're Over 60: Check with your doctor about your RSV risk factors. Aboriginal and Torres Strait Islander adults aged 60 and over, all adults aged 75 and over, and younger adults with chronic conditions should discuss vaccination options.

One important clarification: RSV immunization products are not currently funded for other recommended population groups beyond those specified in the program. However, some products remain available through private prescription for those outside the funded categories.

What Makes This Approach Different?

Australia's strategy represents a significant evolution in infectious disease prevention. Rather than waiting for infants to develop their own immune response, the program leverages maternal antibodies and monoclonal antibody technology to provide immediate, passive protection during the most vulnerable period. This approach has proven effective in clinical settings and addresses a gap that existed before these tools became available.

The expansion to older adults reflects growing recognition that RSV is not solely a pediatric concern. Severe RSV disease in older adults can lead to hospitalization, pneumonia, and complications in those with underlying heart or lung disease. By funding vaccines for this population, Australia joins other countries in acknowledging RSV as a significant public health threat across the lifespan.

The program's rollout demonstrates how public health systems can adapt quickly when new preventive tools become available. For families navigating RSV season, these free protections offer meaningful reassurance during the months when respiratory viruses circulate most widely.